October 9, 2015
Results from a meta-analysis show a reduced risk for anxiety among children with attention-deficit/hyperactivity disorder receiving psychostimulant treatment compared with those receiving placebo.
“Epidemiologic studies have demonstrated that 25% to 50% of children with [attention-deficit/hyperactivity disorder (ADHD)] also have a comorbid anxiety disorder. Anxiety has also been identified as a potential moderator of short-term treatment response in children with ADHD. Previous trial data have suggested that children with ADHD who have comorbid anxiety may exhibit a decreased response to methylphenidate (MPH) and experience more side effects than children with ADHD without anxiety,” Catherine G. Coughlin, BS, of Yale Child Study Center, Yale University School of Medicine, and colleagues wrote.